Quarterly ResultAug 6, 2026, 07:08 AM
Immunocore Q2 KIMMTRAK Revenue $115.9M, up 18% YoY
AI Summary
Immunocore reported Q2 2026 KIMMTRAK net revenues of $115.9 million, an 18% increase year-over-year, and a net loss of $0.8 million. For the first half of 2026, the company achieved a net income of $12.2 million. The company also announced that enrollment in its Phase 3 TEBE-AM trial is nearing completion, with data expected by the end of 2026, and presented positive five-year overall survival data for KIMMTRAK in metastatic uveal melanoma.
Key Highlights
- KIMMTRAK net revenues Q2 2026: $115.9 million, up 18% YoY
- KIMMTRAK net revenues H1 2026: $222.6 million, up 16% YoY
- Net loss Q2 2026: $0.8 million ($0.02 loss per share)
- Net income H1 2026: $12.2 million ($0.23 income per share)
- Cash, cash equivalents, marketable securities: $880.2 million as of June 30, 2026
- R&D expenses Q2 2026: $73.9 million
- SG&A expenses Q2 2026: $43.9 million
- KIMMTRAK 5-year OS rate: 16% vs 8% in control arm for mUM
Price Impact
More from IMCR